Research Comparison
Mazdutide (IBI362 / LY3305677) vs Survodutide (BI 456906)
A side-by-side research comparison of Mazdutide (IBI362 / LY3305677) and Survodutide (BI 456906) drawn from Cobalt Peptides' peptide database records.
Mazdutide (IBI362 / LY3305677)
Mazdutide (IBI362 / LY3305677) is a synthetic analogue of oxyntomodulin acting as a dual glucagon-like peptide-1 (GLP-1) and glucagon receptor agonist. Unlike GLP-1-only or GIP/GLP-1 compounds, it engages the glucagon receptor as well, a mechanism examined in the published literature for its distinct contribution to energy balance. Mazdutide is not an approved medicine and remains in clinical development. Supplied strictly as a research compound for laboratory use.
Survodutide (BI 456906)
Survodutide (BI 456906) is an investigational dual glucagon receptor and GLP-1 receptor agonist. It is a 29-amino acid peptide with C18 fatty acid acylation, a modification that extends its duration of action and supports once-weekly administration in study protocols. Its dual mechanism engages both receptors rather than one, and is the subject of ongoing published research. Survodutide is not an approved medicine. Supplied strictly as a research compound for laboratory use.